Brief: Atea Pharmaceuticals Q4 Basic EPS USD -0.57
05/03/2026 21:05
Mar 05 (Reuters) - Atea Pharmaceuticals Q4 net income USD -44.867 million. Q4 operating income USD -54.934 million Q4 operating expenses USD 54.934 million Q4 pretax profit USD -51.635 million
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM